[PDF][PDF] Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group
PA Meyers, CL Schwartz, MD Krailo… - Journal of clinical …, 2008 - academia.edu
PA Meyers, CL Schwartz, MD Krailo, JH Healey, ML Bernstein, D Betcher, WS Ferguson…
Journal of clinical oncology, 2008•academia.eduPurpose To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate
with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the
treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP)
to chemotherapy enhances event-free survival (EFS) and overall survival in newly
diagnosed patients with osteosarcoma.
with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the
treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP)
to chemotherapy enhances event-free survival (EFS) and overall survival in newly
diagnosed patients with osteosarcoma.
Purpose
To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma.
academia.edu